NASDAQ:QCLS Mymd Pharmaceuticals Q2 2026 Earnings Report $0.75 -0.03 (-3.52%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$0.74 -0.01 (-1.07%) As of 10/2/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Mymd Pharmaceuticals EPS ResultsActual EPS-$0.79Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AMymd Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMymd Pharmaceuticals Announcement DetailsQuarterQ2 2026Date8/12/2026TimeAfter Market ClosesConference Call DateWednesday, August 12, 2026Conference Call Time7:00AM ETConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Mymd Pharmaceuticals Earnings HeadlinesQ/C Technologies Announces Research Collaboration with Sandia National Laboratories, a $5 Billion U.S. Department of Energy LabOctober 1 at 1:47 PM | globenewswire.comQ/C Technologies Announces Research Collaboration with Sandia National Laboratories, a $5 Billion U.S. Department of Energy LabSeptember 30, 2026 | globenewswire.comWATCH THIS BEFORE DECEMBER 8th!!James Altucher says a quiet government filing could reveal Elon Musk's biggest move yet, and almost nobody has noticed it. Altucher believes the filing could matter to as many as 1,806,000 Americans in the years ahead. He explains why Musk buried it and what it could mean, free of charge.October 4 at 1:00 AM | Paradigm Press (Ad)Q/C Technologies Names Yossef Ehrlichman Chief Technology Officer to Lead Optical Processor DevelopmentSeptember 15, 2026 | globenewswire.comQ/C Technologies Appoints Veteran Silicon Photonics Engineer Yossef Ehrlichman as Founding Manager, Photonic Integrated Circuit (PIC) DevelopmentAugust 4, 2026 | globenewswire.comQ/C Technologies Relocates Headquarters to San Francisco in Proximity to World-Class Engineering Experts for Photonic Computing and Optical AI Inference InitiativeJuly 1, 2026 | globenewswire.comSee More Mymd Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Mymd Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mymd Pharmaceuticals and other key companies, straight to your email. Email Address About Mymd PharmaceuticalsMymd Pharmaceuticals (NASDAQ:QCLS) is a clinical-stage biotechnology company focused on developing therapies for diseases associated with aging, chronic inflammation and immune-system dysfunction. Its research has centered on small-molecule drug candidates intended to regulate immune and metabolic pathways. The company’s lead development program has included MYMD-1, an orally administered investigational compound studied for potential applications involving autoimmune disease, chronic inflammation and age-related conditions. MyMD has also evaluated other therapeutic opportunities related to immunometabolic regulation and cannabidiol-based treatments. MyMD Pharmaceuticals has primarily operated as a U.S.-based development-stage biotechnology company, with its activities focused on research, preclinical work and clinical development rather than commercialized products. Publicly available information does not provide enough reliable detail to describe current leadership or to confirm the relationship between MyMD Pharmaceuticals and the ticker symbol QCLS.View Mymd Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/28 - 10/02Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street DividedMcCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestMcDonald's Is Undergoing a Massive New Growth Strategy. Can It Win Back Consumers? Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
